Sugi Predict

Sugi Predict / Compounds / SCHEMBL397257

SCHEMBL397257

SCHEMBL397257

NCCCC[C@H](NC(=O)[C@@H](N)CCC(N)=O)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 2/20 0.55
▸ ALOX15 P16050 1/20 0.49
▸ BLM P54132 1/20 0.49
▸ PMP22 Q01453 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ DPP8 Q6V1X1 2/20 0.48
▸ DPP9 Q86TI2 2/20 0.48
▸ DPP4 P27487 1/20 0.48
▸ GSR P00390 1/20 0.47
▸ NOD1 Q9Y239 3/20 0.44
▸ SLC6A5 Q9Y345 1/20 0.44
▸ CPB2 Q96IY4 4/20 0.43
▸ DPP7 Q9UHL4 1/20 0.43
▸ SLC15A2 Q16348 1/20 0.41
▸ ERAP2 Q6P179 1/20 0.41
▸ ERAP1 Q9NZ08 1/20 0.41
▸ LNPEP Q9UIQ6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5334900 1.00 FOLH1 (0.55) FOLH1ALOX15BLMPMP22KMT2A
SCHEMBL7563979 1.00 FOLH1 (0.55) FOLH1ALOX15BLMPMP22KMT2A
SCHEMBL30148762 1.00 FOLH1 (0.55) FOLH1ALOX15BLMPMP22KMT2A
SCHEMBL27767761 0.98 FOLH1 (0.54) FOLH1ALOX15BLMPMP22KMT2A
SCHEMBL30731560 0.97 FOLH1 (0.52) FOLH1ALOX15BLMPMP22KMT2A
SCHEMBL5336140 0.94 FOLH1 (0.55) FOLH1ALOX15BLMPMP22KMT2A
SCHEMBL5336146 0.94 FOLH1 (0.55) FOLH1ALOX15BLMPMP22KMT2A
SCHEMBL32690574 0.93 FOLH1 (0.55) FOLH1ALOX15BLMPMP22KMT2A
SCHEMBL31376469 0.92 FOLH1 (0.48) FOLH1ALOX15BLMPMP22KMT2A
SCHEMBL31376475 0.92 FOLH1 (0.48) FOLH1ALOX15BLMPMP22KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091078-A1 OLIGOPEPTIDE THAT INHIBITS ANGIOGENESIS AND VASCULAR FUNCTION TRIEBEL JAKOB (DE) 2026-04-02 — — US claimed
US-20230410977-A1 METHODS AND MATERIALS FOR ASSESSING RADIATION EXPOSURE NUTECH VENTURES 2023-12-21 — — US claimed
US-20230107937-A1 ZWITTERIONIC POLYPEPTIDE AND DERIVATIVE THEREOF AND NANODRUG BASED THEREON ZHEJIANG UNIVERSITY (CN) 2023-04-06 — — US claimed
WO-2022140565-A1 METHODS AND MATERIALS FOR ASSESSING RADIATION EXPOSURE NUTECH VENTURES (US) 2022-06-30 — — WO claimed
CN-111560049-B Zwitterionic polypeptide and derivative thereof and nano-drug based on zwitterionic polypeptide and derivative 浙江大学 2022-05-17 — — CN claimed
CN-105683390-B HbA1c measurement method using amadoriase acting on glycosylated peptide 龟甲万株式会社 2021-02-26 — — CN claimed
CN-111560049-A Zwitterionic polypeptide and derivative thereof and nano-drug based on zwitterionic polypeptide and derivative 浙江大学 2020-08-21 — — CN claimed
CN-110862448-A GLP-1 derivative modified by zwitterionic polypeptide and preparation method and application thereof 浙江大学 2020-03-06 — — CN claimed
EP-2776832-A1 BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME Metabolon, Inc. (US) 2014-09-17 — — EP claimed
WO-2013070839-A1 BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME METABOLON, INC. (US) 2013-05-16 — — WO claimed
US-6008256-A COMPRISES (A) LIDOCAINE, (B) EPINEPHRINE IN SPECIFIC AMOUNT, AND (C) ONE OR MORE AMINO ACIDS; EXCELLENT STORAGE STABILITY SHOWA YAKUHIN KAKO CO., LTD. (JP) 1999-12-28 — — US claimed
EP-0858803-A1 COMPOSITION FOR LOCAL ANESTHESIA Showa Yakuhin Kako Co. Ltd (JP) 1998-08-19 — — EP claimed
EP-4704800-A1 COMPOSITIONS COMPRISING KOMBUCHA AND THEIR USES Coty Inc. (US) 2026-03-11 — — EP disclosed
EP-4684030-A2 METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP Martin-Luther-Universität Halle-Wittenberg (DE) 2026-01-28 — — EP disclosed
US-20260014538-A1 Granular Aerogel Scaffolds and Methods of Making and Using the Same THE PENN STATE RESEARCH FOUNDATION (US) 2026-01-15 — — US disclosed
US-20250298022-A1 HIV GP41 VARIANTS FOR IMMUNODIAGNOSTIC ASSAYS ROCHE DIAGNOSTICS GMBH (DE) 2025-09-25 — — US disclosed
EP-0672142-A1 MULTIVALENT AND MULTISPECIFIC BINDING PROTEINS, THEIR MANUFACTURE AND USE MEDICAL RESEARCH COUNCIL (GB) 1995-09-20 — — EP disclosed
US-5366958-A Localized delivery using fibronectin conjugates THE LIPOSOME COMPANY, INC. (US) 1994-11-22 — — US disclosed
WO-1994013804-A1 MULTIVALENT AND MULTISPECIFIC BINDING PROTEINS, THEIR MANUFACTURE AND USE MEDICAL RESEARCH COUNCIL (GB) 1994-06-23 — — WO disclosed
US-3994688-A REACTING L-LYSINE WITH A G-FORMYL-PYRIDINE DERIVATIVE A/S N. FOSS ELECTRIC (DK) 1976-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230107937-A1 ZWITTERIONIC POLYPEPTIDE AND DERIVATIVE THEREOF AND NANODRUG BASED THEREON VIP, NGLY1, CD47 FOLH1 2068/4885ALOX15 4652/4885BLM 3401/4885
US-20260014538-A1 Granular Aerogel Scaffolds and Methods of Making and Using the Same CALD1, CALCB, FGB FOLH1 3693/4885ALOX15 3990/4885BLM 1318/4885
US-20260091078-A1 OLIGOPEPTIDE THAT INHIBITS ANGIOGENESIS AND VASCULAR FUNCTION FLT4, RXFP4, RXFP3 FOLH1 2202/4885ALOX15 1742/4885BLM 2688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.